Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
Bilal H, Bergen PJ, Tait JR, Wallis SC, Peleg AY, Roberts JA, Oliver A, Nation RL, Landersdorfer CB. Bilal H, et al. Among authors: tait jr. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00469-20. doi: 10.1128/AAC.00469-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366710 Free PMC article.
Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
Agyeman AA, Rogers KE, Tait JR, Bergen PJ, Kirkpatrick CM, Wallis SC, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB. Agyeman AA, et al. Among authors: tait jr. Clin Pharmacol Ther. 2021 Apr;109(4):1104-1115. doi: 10.1002/cpt.2191. Epub 2021 Mar 12. Clin Pharmacol Ther. 2021. PMID: 33550617
Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
Tait JR, Bilal H, Kim TH, Oh A, Peleg AY, Boyce JD, Oliver A, Bergen PJ, Nation RL, Landersdorfer CB. Tait JR, et al. J Glob Antimicrob Resist. 2021 Sep;26:55-63. doi: 10.1016/j.jgar.2021.04.021. Epub 2021 May 21. J Glob Antimicrob Resist. 2021. PMID: 34023531 Free article.
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
Bilal H, Tait JR, Lang Y, Zhou J, Bergen PJ, Peleg AY, Bulitta JB, Oliver A, Nation RL, Landersdorfer CB. Bilal H, et al. Among authors: tait jr. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0220321. doi: 10.1128/aac.02203-21. Epub 2022 Jan 18. Antimicrob Agents Chemother. 2022. PMID: 35041509 Free PMC article.
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB. Breen SKJ, et al. Among authors: tait jr. Int J Antimicrob Agents. 2024 Jun;63(6):107161. doi: 10.1016/j.ijantimicag.2024.107161. Epub 2024 Mar 30. Int J Antimicrob Agents. 2024. PMID: 38561094 Free article.
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Tait JR, Bilal H, Rogers KE, Lang Y, Kim TH, Zhou J, Wallis SC, Bulitta JB, Kirkpatrick CMJ, Paterson DL, Lipman J, Bergen PJ, Roberts JA, Nation RL, Landersdorfer CB. Tait JR, et al. Antibiotics (Basel). 2022 Jan 13;11(1):101. doi: 10.3390/antibiotics11010101. Antibiotics (Basel). 2022. PMID: 35052977 Free PMC article.
55 results